Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University Medical Center Groningen
This study is a retrospective cohort study. A database will be created from the data available of all patients that have participate in the named patient program for pembrolizumab in the Netherlands. This database will be used for analysis of response markers and for an evaluation of adverse events.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
All patients that were eligible for treatment with pembrolizumab in the Named Patient Program in the Netherlands.
Clareo Health | Retrospective Analysis of Response Markers and Adverse Events in Melanoma Patients Treated With Pembrolizumab
